Investigation of dyslipidaemias

Journal of Clinical Pathology

Volumn 50, Issue 9, 1997, Pages 721-734

  Winder, A F ^a   Richmond, W ^c   Vallance, D T ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOLIPOPROTEIN; LIPOPROTEIN A; TRIACYLGLYCEROL LIPASE;

CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC ACCURACY; DYSLIPIDEMIA; INTERMETHOD COMPARISON; LIPID ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; REVIEW; BLOOD; HUMAN; HYPERLIPIDEMIA; OXIDATION REDUCTION REACTION; PRACTICE GUIDELINE;

APOLIPOPROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; HUMANS; HYPERLIPIDEMIAS; LIPASE; LIPOPROTEIN(A); LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PRACTICE GUIDELINES; TRIGLYCERIDES;

EID: 0030879120     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.9.721     Document Type: Review

References (84)

1. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970;43:891-915.
2. Mann JI, Lewis B, Shepherd J, Winder AF, Fenster S, Rose L, et al. Blood lipids and other cardiovascular risk factors; their prevalence in Britain. BMJ 1988;296:1702-6.
3. Betteridge DJ, Dodson PM, Hughes EA, Laker MF, Nicholls PM, Rees JAE, et al. Management of hyperlipidaemia - guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993;69:359-69.
4. Stein Y. Comparison of European and USA guidelines for prevention of coronary heart disease. Atherosclerosis 1994; 110(Suppl):S41-4.
5. Mount JN, Rao S, Miller K, Hammett F, Whiting C, Lewis B. Laboratory investigation of lipid disorders. ACP Broadsheet 101. Hove: Association of Clinical Pathologists, 1982.
6. Richmond W. Analytical reviews in clinical chemistry: the quantitative analysis of cholesterol. Ann Clin Biochem 1992;29:577-97.
7. Laker MF, Evans K. Analysis of apolipoproteins. Ann Clin Bioehem 1996;33:3-30.
8. Klotzsch SG, McNamara JR. Triglyceride measurements: a review of methods and interferences. Clin Chem 1990;36: 1605-13.
9. Rifai N, Warnick GR. Laboratory measurement of lipids, lipoproteins and apolipoproteins. Washington, DC: AACC Press, 1994:1-357.
10. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults, (adult treatment panel II). JAMA 1993;269:3013-23.
11. Pelletier O, Wright LA, Breckenridge WC. Isotope dilution mass spectrometry of serum cholesterol with (3,4-13C)cholesterol: proposed definitive method. Clin Chem 1987;33:1403-11.
12. Duncan IW, Mather A, Cooper GR. The procedure for the proposed cholesterol reference method. [Available on request from GR Cooper, Centers for Disease Control and Prevention, Atlanta, GA 3033 USA]. Atlanta: CDC, 1982.
13. Steinhausen RL, Price CP. Principles and practice of dry chemistry systems. In: Marks V, Alberti KGMM, eds. Recent advances in clinical biochemistry, III. London: Churchill Livingstone, 1985:273-91.
14. Winder AF, Jagger C, Garrick DP, Vallance D, Butowski P, Anderson J, et al. Lipid screening in an elderly population. Difficulty in interpretation and in detection of occult metabolic disease. J Clin Pathol 1996;49:278-83.
15. Ferrara A, Barrett-Connor E, Shan J. Total, LDL and HDL cholesterol decrease with age in older men and women. The Rancho Bernado Study. 1984-1994. Circulation 1997; 96:37-43.
16. Siedel J, Hagele EO, Ziegenhorn J, Wahlenfeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29: 1075-80.
17. Lofland HB Jr. A semiautomated method for the determination of triglycerides in serum. Anal Biochem 1964;9:393-400.
18. Oleesky DA, Hakeem V. Congenital adrenal hypoplasia and glycerol kinase deficiency. Acta Paediatr Scand 1989;78: 893-5.
19. Gotto AM jr, Patsch J, Yamamoto A. Postprandial lipaemia. Am J Cardiol 1991;68:11A-12A.
20. Lippel K. Report of the high-density lipoprotein methodology workshop. Bethesda: NIH publication 79-1661, August 1979.
21. Vallance DT, Byrne D, Winder AF. Precipitation procedures used to isolate HDL with particular reference to effects on apo A-I-only particles and lipoprotein(a). Clin Chim Acta 1994;229:77-85.
22. Havel RJ, Eder HH, Bragdon JH. The distribution and chemical composition of ultra-centrifugally-separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
23. Li KM, Wilcken DE, Dudman NPB. Effect of serum lipoporotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. Clin Chem 1994;40: 571-3.
24. Wiebe DA, Smith SJ. Six methods for isolating high-density lipoprotein compared, with use of the reference method for quantifying cholesterol in serum. Clin Chem 1985;31:746-50.
25. Nauck M, Marz W, Haas B, Wieland H. Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated. Clin Chem 1996;42:424-9.
26. Barter PJ, Rye KA. High-density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.
27. Fruchart JC, Ailhaut G. Apolipoprotein A-containing particles: physiological role, quantification and clinical significance. Clin Chem 1992;38:793-7.
28. Vallance DT, Staunton A, Winder AF. Limited discriminant value of LpAI, Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease. J Clin Pathol 1995;48:70-4.
29. Huang Y, von Eckardstein A, Wu S, Assmann G. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995;15:1412-28.
30. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham study. Ann Epidemiol 1992;2:23-8.
31. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.
32. Hong MK, Romm PA, Reagan K, Green CH, Rackley CE. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. Am J Cardiol 1991;68:1646-50.
33. Neil HAW, Mant D, Jones L, Morgan B, Mann JI. Lipid screening: is it enough to measure total cholesterol concentration? BMJ 1990;301:584-7.
34. Mann KG. Factor VII assays, plasma triglyceride levels and cardiovascular disease risk. Arteriosclerosis 1989;9:783-4.
35. Assmann G, von Eckardstein A, Funke H. Mutations in apolipoprotein genes and HDL metabolism. In: Rosseneu M, ed. Structure and Junction of apolipoproteins. Boca Raton: CRC Press, 1992:85-122.
36. Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse cholesterol transport of cholesterol and coronary artery disease. Insights from mutations. Circulation 1993;87(Suppl III):28-34.
37. Day INM, Humphries SE. Electrophoresis for genotyping: microtitre array diagonal gel electrophoresis (MADGE) on horizontal polyacrylamide (H-PAGE) gels, Hydrolink or agarose. Anal Biochem 1994;222:389-95.
38. Marcil M, Boucher B, Krimbou L, Solmoss BC, Davignon J, Frohlich J, et al. Severe familial HDL deficiency in French-Canadian kindreds. Aneriosder Thromb Vasc Biol 1995;15:1015-24.
39. Rumsey SC, Galeano NF, Arad Y, Deckelbaum RJ. Cryop-reservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res 1992;33:1551-61.
40. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma without use of the ultracentrifuge. Clin Chem 1972;18:499-502.
41. Cobbaert C, Broodman I, Swart GR, Hoogerbrugge N. Performance of a direct immuno-separation based LDL-cholesterol method compared to Friedewald calculation and a polyvinyl sulphate precipitation method. Eur J Clin Chem Clin Biochem 1995;33:417-24.
42. Krauss RM, Blanche PJ. Detection and quantitation of LDL subtractions. Curr Opinion Lipidol 1992;3:377-83.
43. Campos H, Genest JJ Jr, Blijlevens E, Mcnamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12: 187-95.
44. Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis 1996;118:111-22.
45. Rajman I, Kendall MJ, Cramb R, Holder RL, Salih M, Gammage MD. Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis 1996;125:231-42.
46. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
47. Puhl H, Waeg G, Esterbauer H. Methods to determine oxidation of low-density lipoproteins. Methods Enzymol 1994; 233:425-41.
48. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff SP. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 1994;220:403-9.
49. Tribble DL, Krauss RM, Lansberg MG, Thiel PM, van den Berg JJM. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res 1995;36:662-71.
50. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidised LDL. Arterioscler Thromb Vasc Biol 1995;15:441-5.
51. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Alba Y, et al. An endothelial receptor for oxidised low-density lipoprotein. Nature 1997;386:73-7.
52. Winder AF. Antioxidants, cholesterol and ischaemic heart disease: CHAOS or confusion? J Clin Pathol 1997;50:269-70.
53. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246:904-16.
54. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standard isoform nomenclature. Clin Chem 1996;42:436-9.
55. Seed M, Hoppichler H, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia. N Engl J Med 1990;322:1494-9.
56. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995;15:850-5.
57. Mackness MI, Bhatnagar D, Weiringa G, Mbewu A, Haynes B, Durrington PN. A comparative study of six commercial lipoprotein(a) assays in seventeen laboratories within the British Isles. Ann Clin Biochem 1996;33:63-70.
58. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4.
59. Hiraga T, Shimada M, Okubo M, Nakashini K, Kobayashi T, Murase T. Lipoprotein(a) is an independent risk factor for multiple cerebral infarctions. Atherosclerosis 1996;122: 29-32.
60. Lovegrove JA, Isherwood G, Jackson KG, Williams CM, Gould B. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Biochim Biophys Acta 1996; 1301:221-9.
61. Talmud P. Detection and phsiological relevance of mutations in the apoproiein E, C-II, and B genes. In: Rosseneu M, ed. Structure and function of apolipoproteins. Boca Raton: CRC Press, 1992:123-58.
62. Bao W, Srinivasan SR, Berenson CJ. Tracking of serum apolipoproteins A-I and B in children and young adults: the Bogalusa Heart Study. J Clin Epidemiol 1993;46:609-16.
63. Sniderman AD. The measurement of apolipoprotein B should replace the conventional lipid profile in screening for cardiovascular risk. Can J Cardiol 1992;8:133-8.
64. McDowell IFW, Wisdom GB, Trimble HR. Apolipoprotein 1: phenotype determined by agarose gel electrofocussing and immunoblotting. Clin Chem 1989;35:2070-3.
65. Bolla MK, Haddad L, Humphries SE, Winder AF, Day INM. High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Clin Chem 1995;41:1599-604.
66. Harake B, Caines PSM, Thibert RJ, Cheung RMC. A simple micromethod for rapid assessment of the distribution of apolipoprotein C isoforms in very low density lipoprotein. Clin Biochem 1991;24:255-60.
67. Seed M, Mailly F, Vallance D, Doherty E, Winder A, Talmud P, Humphries SH. Lipoprotein lipase activity in patients with combined hyperlipidaemia. Clinical Investigator 1994;72:100-6.
68. Henderson AD, Richmond W, Elkeles RS. Hepatic and lipoprotein lipases selectively assayed in post-heparin plasma. Clin Chem 1993;39:218-23.
69. Rifai N, Durour DR, Cooper GR. Preanalytical variations in lipid, lipoprotein and apolipoprotein testing. In: Rifai N, Warnick GR, eds. Laboratory measurement of lipids, lipoproteins and apolipoproteins. Washington, DC: AACC Press, 1994;43-64.
70. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313:981-5.
71. Kihara S, Matsuzawa Y, Kubo M, Nozaki S, Funahashi T, Yamashita S, et al. Autoimmune hyperchylomicronaemia. N Engl J Med 1989;320:1255-9.
72. Goldstein JL, Hobbs H, Brown MS. Familial Hypercholesterolomia. In: Scriver CR, Beaudet AL, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th edn, Vol 2, 1995:1981-2030.
73. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the receptor gene in familial hypercholesterolaemia. Human Mutation 1992;1:445-66.
74. Koivisto PVI, Koivisto U-M, Kovanen PT, Gylling H, Miettinen TA, Kontula K. Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesternkiemia. Arterioscler Thromb 1993;13:1680-8.
75. Graadt van Roggen JF, van der Westhuyzen DR, Coetzee GA, Marais AD, Steyn K, Langenhoven E, et al. FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol 1995;15:765-72.
76. Gudnason V, King-Underwood L, Seed M, Sun XM, Soutar AK, Humphries SM. Identification of recurrent and novel mutations in exon 4 of the LDL receptor gene in patients with familial hypercholesterolaemia in the United Kingdom. Arterioscler Thromb 1993;13:56-63.
77. Schmitz G, Bruning T, Kovacz E, Barlage S. Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in the differential diagnosis of hypercholesterolemia. Arterioscler Thromb 1993;13:1053-65.
78. Stephan Z, Yurachek EC. Rapid fluorimetric assay of LDL receptor activity by Di-I-labelled LDL. J Lipid Res 1993;34:325-30.
79. Wray R, Heil HAW, Rees JAE. Screening tor hyperlipidaemia in childhood. J Roy Coll Phys 1996;30:115-18.
80. Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, McNamara PM, Dalen JE. Validity of total serum cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol 1984;54:722-5.
81. Bachorik PS, Ross KW. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 1995;41:1414-20.
82. Stein EA, Myers GL. National cholesterol education program recommendations for triglyceride measurement: executive summary. Clin Chem 1995;41:1421-6.
83. Bachorik PS, Ross KW. National cholesterol education program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin Chem 1995;41:1427-33.
84. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardisation project for measurements of apolipoproteins A-I and B. Clin Chem 1994;40:586-92.